Sign up for updates. Be part of our community.

Christopher Cashman

Former Chairman and Chief Executive Officer, Marinus Pharmaceuticals, Inc.

Mr. Cashman has been a director of the Science Center since 2010. He is a recognized leader in the biopharmaceutical industry and has decades of experience leading life sciences companies. Mr. Cashman is currently Board Chair at MBF Therapeutics Inc.

From 2011 until 2019, he served as Chairman and Chief Executive Officer of Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, based in Radnor, Pennsylvania, focused on developing and commercializing innovative therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. Prior to Marinus, Mr. Cashman provided consulting services to Quaker Partners, a private venture capital fund. Prior to Quaker, he served as President and Chief Executive Officer of Protez Pharmaceuticals, Inc., a company specializing in the development of antibiotics that he co-founded in 2003. Protez was acquired by Novartis in 2008.

Mr. Cashman has enjoyed a career spanning three decades in the pharmaceutical industry, including prior roles as President and Chief Executive Officer, Message Pharmaceuticals Inc., and as Vice President, Sales and Marketing, for both Pfizer and SmithKline Beecham. He began his pharmaceutical career at SmithKline Corporation.

Mr. Cashman currently serves on the board of Life Sciences Pennsylvania. He was the recipient of the “Entrepreneur of the Year” award by the Mid Atlantic Capital Alliance in 2008 and the “Life Sciences CEO of the Year” by the Eastern Pennsylvania Technology Council.

Mr. Cashman holds a B.S. in business management from the University of Minnesota and a M.S. in economics from Purdue University.